Maïlis Lauwers, Philippe Akiki, Samy Bensaid, Saad Bakrim, Mélanie Monfort, Hanane El Kenz
{"title":"Comparative analysis of serological reactivity in genetically confirmed Rh variants within a recipient population.","authors":"Maïlis Lauwers, Philippe Akiki, Samy Bensaid, Saad Bakrim, Mélanie Monfort, Hanane El Kenz","doi":"10.1111/vox.70285","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Detecting Rh variants in transfusion recipients is essential to prevent alloimmunization. This study compared the serological reactivity of various monoclonal antibodies using two techniques (gel column agglutination and microplate technology at room temperature) in relation to genetically confirmed Rh variants.</p><p><strong>Materials and methods: </strong>Over an 18-month period, all EDTA blood samples referred to the molecular laboratory were analysed. RHD and RHCE genotyping was performed, and samples carrying at least one variant allele underwent serological testing. Statistical analysis was performed using the McNemar test (p < 0.05).</p><p><strong>Results: </strong>Among 610 samples, 118 (19%) carried at least one Rh variant. The most frequent alleles were RHCE*CeRN (n = 39) and RHD*weak D type 1 (n = 14). Weak RhD (types 1 and 3) and partial RhD from RHD*DAR were serologically weakened (<4+) with both methods. Homozygosity for RHCE*CeRN was suggested by serological weakening of RH5 with both methods, whereas heterozygosity was indicated by serological weakening of RH2 with microplate only. Other variants with a few samples (RH1 of RHD*weak D type 2 and 5, RH2 of RHD*RHD-CE (4-7)-D, RH3 of RHCE*cEIV, RH4 of RHCE*ceJAL and RH5 of RHCE*ceMO.01 and RHCE*ceAR) showed weak serological intensities but lacked statistical confirmation. Finally, 39% of Rh variants were not detected as serologically weakened by both serological methods.</p><p><strong>Conclusion: </strong>Phenotyping remains the first-line screening tool. Weak serological intensities help guide molecular investigations. However, detection of Rh variants using serology alone is highly variable. Combining different clones and techniques improves sensitivity.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70285","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Detecting Rh variants in transfusion recipients is essential to prevent alloimmunization. This study compared the serological reactivity of various monoclonal antibodies using two techniques (gel column agglutination and microplate technology at room temperature) in relation to genetically confirmed Rh variants.
Materials and methods: Over an 18-month period, all EDTA blood samples referred to the molecular laboratory were analysed. RHD and RHCE genotyping was performed, and samples carrying at least one variant allele underwent serological testing. Statistical analysis was performed using the McNemar test (p < 0.05).
Results: Among 610 samples, 118 (19%) carried at least one Rh variant. The most frequent alleles were RHCE*CeRN (n = 39) and RHD*weak D type 1 (n = 14). Weak RhD (types 1 and 3) and partial RhD from RHD*DAR were serologically weakened (<4+) with both methods. Homozygosity for RHCE*CeRN was suggested by serological weakening of RH5 with both methods, whereas heterozygosity was indicated by serological weakening of RH2 with microplate only. Other variants with a few samples (RH1 of RHD*weak D type 2 and 5, RH2 of RHD*RHD-CE (4-7)-D, RH3 of RHCE*cEIV, RH4 of RHCE*ceJAL and RH5 of RHCE*ceMO.01 and RHCE*ceAR) showed weak serological intensities but lacked statistical confirmation. Finally, 39% of Rh variants were not detected as serologically weakened by both serological methods.
Conclusion: Phenotyping remains the first-line screening tool. Weak serological intensities help guide molecular investigations. However, detection of Rh variants using serology alone is highly variable. Combining different clones and techniques improves sensitivity.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.